SCHEMBL7397200

SCHEMBL7397200

NC(CCc1cc(O)c(C(c2cccc(NS(=O)(=O)c3ccccc3)c2)C2CC2)c(=O)o1)C(=O)NC(CO)(CO)CO

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP1LC3B Q9GZQ8 1/20 0.34
MAP1LC3A Q9H492 1/20 0.34
HTR6 P50406 4/20 0.33
CA1 P00915 2/20 0.32
CA2 P00918 2/20 0.32
TGFBR1 P36897 1/20 0.32
PTGES O14684 1/20 0.31
FABP4 P15090 1/20 0.31
GBA1 P04062 1/20 0.31
KMT2A Q03164 1/20 0.31
BTK Q06187 1/20 0.31
HSD17B1 P14061 2/20 0.30
HSD17B2 P37059 2/20 0.30
PDE4B Q07343 1/20 0.30
GAA P10253 1/20 0.30
GFER P55789 1/20 0.30
APOBEC3G Q9HC16 1/20 0.30
POLB P06746 1/20 0.30
F2 P00734 1/20 0.30
F10 P00742 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7405918 0.90 LMNA (0.32) GAA
SCHEMBL7403242 0.88 MMP2 (0.31)
SCHEMBL7402162 0.88
SCHEMBL7407740 0.87 CBLB (0.33)
SCHEMBL7402046 0.87 MAP1LC3B (0.34) MAP1LC3BMAP1LC3AHTR6PTGESGBA1
SCHEMBL7404889 0.87 HSD17B1 (0.36) HSD17B1HSD17B2
SCHEMBL7397192 0.85 GHSR (0.34) MAP1LC3BMAP1LC3AHTR6TGFBR1PTGES
SCHEMBL7397205 0.84 CA1 (0.35) MAP1LC3BMAP1LC3AHTR6CA1CA2
SCHEMBL7401187 0.84 HTR6 (0.38) MAP1LC3BMAP1LC3AHTR6TGFBR1GAA
SCHEMBL7402044 0.81 MAP1LC3B (0.33) MAP1LC3BMAP1LC3AHTR6CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210246125-A1 PYRANONE COMPOUNDS USEFUL TO MODULATE OMA1 PROTEASE 712 NORTH INC. 2021-08-12 US claimed
WO-1995030670-A2 PYRANONE COMPOUNDS USEFUL TO TREAT RETROVIRAL INFECTIONS PHARMACIA & UPJOHN COMPANY (US) 1995-11-16 WO claimed
US-5852195-A Pyranone compounds useful to treat retroviral infections PHARMACIA & UPJOHN COMPANY (US) 1998-12-22 US disclosed
WO-1995030670-A2 PYRANONE COMPOUNDS USEFUL TO TREAT RETROVIRAL INFECTIONS PHARMACIA & UPJOHN COMPANY (US) 1995-11-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210246125-A1 PYRANONE COMPOUNDS USEFUL TO MODULATE OMA1 PROTEASE OPA1, OLA1, PITRM1 MAP1LC3B 814/4885MAP1LC3A 478/4885HTR6 3769/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.